5:07 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Company News

Gilead acquiring synthetic CAR T company Cell Design

Gilead Sciences Inc. (NASDAQ:GILD) will acquire Cell Design Labs Inc. (San Francisco, Calif.) for $175 million up front, plus up to $322 million in milestones payable to Cell Design’s shareholders. Cell Design President and CEO Brian Atwood told BioCentury that Gilead’s interest in the synthetic biology company stemmed from Cell Design’s CAR T partnership with...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >